Gyre Therapeutics, Inc.
GYRE
$8.51
-$0.30-3.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 113.00% | -2,033.69% | -3,059.62% | -33,680.46% | -3,148.78% |
| Total Depreciation and Amortization | 42.55% | 55.08% | 39.06% | 25.66% | -7.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -94.51% | 515.68% | 397.21% | 471.35% | 576.89% |
| Change in Net Operating Assets | -236.70% | -2,262.89% | -59.00% | 208.65% | 322.27% |
| Cash from Operations | -114.06% | -88.66% | -39.43% | 18.31% | 122.29% |
| Capital Expenditure | 72.82% | 41.94% | 25.71% | -13.23% | -67.69% |
| Sale of Property, Plant, and Equipment | -39.61% | -13.48% | 495.52% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.94% | -17.15% | -87.62% | -80.20% | -73.92% |
| Cash from Investing | -0.63% | 25.68% | -7.50% | -19.77% | -34.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1,452.00% | -583.74% | -- | -- |
| Cash from Financing | -15.92% | 2,980.44% | 1,324.76% | 2,789.30% | 13,257.89% |
| Foreign Exchange rate Adjustments | 8.39% | 114.45% | 110.73% | 67.83% | 84.24% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -360.33% | -477.43% | -12.36% | 174.39% | 266.60% |